JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Issues journals

Medical Radiology and Radiation Safety. 2023. Vol. 68. № 3

DOI: 10.33266/1024-6177-2023-68-3-71-77

A.A. Labushkina, O.E. Klement’eva, G.E. Kodina, A.S. Samoilov

Development of Methodological Documents Regulating
the Clinical Trials of New Radiopharmaceutical Drugs

A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia

Contact person: Anna A. Labushkina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Contents

Introduction

The forms of radiopharmaceutical drugs clinical trial protocols

The forms of the researcher’s brochure for clinical studies of radiopharmaceutical drugs

The forms of reports on the results of clinical trials for radiopharmaceutical drugs

Conclusion

Keywords: clinical studies, radiopharmaceutical drug, rules of good clinical practice, researcher’s brochure, protocol of clinical research, normative documentation

For citation: Labushkina AA, Klementyeva OE, Kodina GE, Samoilov AS. Development of Methodological Documents Regulating the Clinical Trials of New Radiopharmaceutical Drugs. Medical Radiology and Radiation Safety. 2023;68(3):71–77. (In Russian). DOI: 10.33266/1024-6177-2023-68-3-71-77

 

References

1. Kobyakova O.S., Kulikov E.S., Deev I.A., Dmitriev A.A., Tabakaev N.A., Pimenov I.D., Tyufilin D.S. Analysis of International Requirements for Designing of Clinical Trials. Razrabotka i Registratsiya Lekarstvennykh Sredstv = Drug Development & Registration. 2016;2:172-178 (In Russ.).

2. Verbruggen A., Coenen H.H., Deverre J.R., Guilloteau D., Langstrom B., Salvadori P.A., Halldin C. Guideline to Regulations for Radiopharmaceuticals in Early Phase Clinical Trials in the EU. Eur. J. Nucl. Med. Mol. Imaging. 2008;35;11:2144-2151. doi: 10.1007/s00259-008-0853-7.

3. Peñuelas I., Vugts D.J., Decristoforo C., et al. The New Regulation on Clinical Trials in Relation to Radiopharmaceuticals: When and How Will It Be Implemented? EJNMMI Radiopharm. Chem. 2019;4;2:2. doi: 10.1186/s41181-019-0055-6.

 

 

 PDF (RUS) Full-text article (in Russian)

 

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.01.2022. Accepted for publication: 25.02.2023.

 

 

 

Medical Radiology and Radiation Safety. 2023. Vol. 68. № 3

DOI: 10.33266/1024-6177-2023-68-3-80-84

A.N. Koterov1, L.N. Ushenkova1, A.A. Wainson2

Nuclear Workers – on the Question of Unification
of Russian-Language Terminology (Brief Report)

1 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia

2 N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Contact person: Aleksey N. Koterov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Abstract

The issue of terminology is considered when searching for sources for analytical and synthetic studies of effects among workers in the nuclear industry (nuclear fuel cycle for the production of nuclear weapons components and fuel for power or transport installations). It is noted that if there are relatively few English-language names of this professional group (only four were found) with the absolute prevalence of the term ‘nuclear workers’, then for Russian-language sources there is a wide variety of names (various combinations with ‘atomic’ and ‘nuclear’ ‘industry’ or ‘industry’ etc.) without a hint of specificity. It is concluded that in the Russian-language literature it is most appropriate to use the term ‘workers in the nuclear industry’ [=nuclear workers], given that the name ‘nuclear industry’ is official.

Keywords: nuclear workers, terminology

For citation: Koterov AN, Ushenkova LN. Wainson AA. Nuclear Workers – on the Question of Unification of Russian-Language Terminology (Brief Report). Medical Radiology and Radiation Safety. 2023;68(3):80–84. (In Russian). DOI: 10.33266/1024-6177-2023-68-3-80-84

 

References

1. Koterov A.N., Ushenkova L.N., Kalinina M.V., Biryukov A.P. Brief Review of World Researches of Radiation and Non-Radiation Effects in Nuclear Industry Workers. Mediko-Biologicheskiye Problemy Zhiznedeyatelnosti = Medical and Biological Problems of Life Activity. 2020;1:17–31 (In Russ.).

2. Koterov A.N., Ushenkova L.N., Kalinina M.V., Biryukov A.P. Comparison of the Risk of Mortality from Solid Cancers after Radiation Incidents and Occupational Exposures. Meditsina Truda i Promyshlennaya Ekologiya = Russian Journal of Occupational Health and Industrial Ecology. 2021;61;9:580–587. https://doi.org/10.31089/1026-9428-2021-61-9-580-587 (In Russ.).

3. Koterov A.N., Tukov A.R., Ushenkova L.N., Kalinina M.V., Biryukov A.P. Average Accumulated Radiation Doses for World Nuclear Workers: Low Doses, Low Effects. Comparison with Doses for Medical Radiologists. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2022;62;3:227–239. https://doi.org/10.31857/S0869803122030043 (In Russ.).

4. Bekman I.N. Yadernaya Industriya = Nuclear Industry. Lecture Course. Moscow Publ., 2005. 867 p. (In Russ.).

5. Novikov G.A. Reflections on the Development of the Concept and Structure of the Draft Law Regulating Relations in the Field of Activities of the Nuclear Weapons Complex for the Use of Nuclear Energy for Defense Purposes. URL: http://www.proatom.ru/modules.php?name=News&file=article&sid=4683 (Date of Access: 30.12.2022) (In Russ.).

6. Wing S. Basics of Radiation Epidemiology // Radiation Health. Effects. Ed. Burdman G.M., Kaplan L. Seattle, Hanford Health Information Network, 1994. URL: http://www.geocities.ws/irradiated45rems/7page6.html (Date of Access: 30.12.2022).

7. Boice J.D.Jr. Ionizing Radiation // Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. Ed. Schottenfeld D., Fraumeni J.F. New York, Oxford University Press, 2006.
P. 259–293.

8. Boice J.D.Jr. Lauriston S. Taylor Lecture: Radiation Epidemiology – the Golden Age and Future Challenges. Health Phys. 2011;100;1:59–76. doi: 10.1097/HP.0b013e3181f9797d.

9. Boice J.D., Held K.D., Shore R.E. Radiation Epidemiology and Health Effects Following Low-Level Radiation Exposure.
J. Radiol. Prot. 2019;39;4:S14–27. https://doi.org/10.1088/1361-
6498/ab2f3d.

10. Zeeb H., Merzenich H., Wicke H., Blettner M. Radiation Epidemiology // Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. Ed. Thun M.J., et al. New York, Oxford University Press, 2018. P. 2003–2037.

11. Berrington de Gonzalez A., Bouville A., Rajaraman P., Schubauer-Berigan M. Ionizing Radiation Schottenfeld and Fraumeni Cancer Epidemiology and Prevention. Ed. Thun M.J., Linet M.S., Cerhan J.R., Haiman C., Schottenfeld D. New York, Oxford University Press, 2018. P. 227–248.

12. The Effects of Low and Very Low Doses of Ionizing Radiation on Human Health. Ed. WONUC. Elsevier Science B.V. 2000. 560 p.

13. URL: https://www.industriall-union.org/who-we-are (Date of Access: 30.12.2022).

14. ICRP Publication 118. ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs – Threshold Doses for Tissue Reactions in a Radiation Protection Context // Annals of the ICRP. Ed. Clement C.H. Amsterdam – New York, Elsevier, 2012. 325 p.

15. National Research Council, Division on Earth and Life Studies, Board on Radiation Effects Research, Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII. Phase 2. National Academies Press, 2006. 422 p.

16. NCRP. Commentary No 27. Implications of Recent Epidemiologic Studies for the Linear-Nonthreshold Model and Radiation Protection. National Council on Radiation Protection and Measurements, Bethesda, MD, 2018. 2 p.

17. IAEA 2018. Industrial Safety Guidelines for Nuclear Facilities. Nuclear Energy Series. No. NP-T-3.3. Vienna, International Atomic Energy Agency, 2018. 261 p.

18. UNSCEAR 1962. Report to the General Assembly, with Scientific Annex. Annex G. Medical, Occupational and Other Exposures. United Nations. New York, 1962. P. 375–413.

19. UNSCEAR 1972. Report to the General Assembly, with Scientific Annex. V. I. Level. Annex C. Doses from Occupational Exposure. United Nations. New York. 1972. P. 173–186.

20. UNSCEAR 1977. Report to the General Assembly, with Scientific Annex. Annex E. Doses from Occupational Exposure. United Nations. New York, 1977. P. 223–300.

21. UNSCEAR 1982. Report to the General Assembly, with Scientific Annex. Annex H. Occupational Exposure. United Nations. New York, 1982. P. 371–423.

22. UNSCEAR 1993. Report to the General Assembly, with Scientific Annex. Annex D. Occupational radiation exposure. United Nations. New York, 1993. P. 375–549.

23. UNSCEAR 2000. Report to the General Assembly, with Scientific Annex. V. I. Annex D. Occupational radiation exposure. United Nations. New York. 2000. P. 497–654.

24. UNSCEAR 2008. Report to the General Assembly, with Scientific Annex. V. I. Annex B. Exposures of the Public and Workers from Various Sources of Radiation. United Nations. New York, 2010. P. 221–463.

25. UNSCEAR 2017. Report to the General Assembly, with Scientific Annex. Exposures of Workers to Ionizing Radiation. Draft A/AC.82/R.725. 17 April 2017. Technical Report. United Nations, 2017. 26 p.

26. UNSCEAR 2019. Report to the General Assembly, with Scientific Annex. Evaluation of Occupational Exposures to Ionizing Radiation. Draft A/AC.82/R.735. 29 April 2019. Technical Report. United Nations, 2019. 154 p.

27. Ashmore J.P., Krewski D., Zielinski J.M., Jiang H., Semenciw R., Band P.R. First Analysis of Mortality and Occupational Radiation Exposure Based on the National Dose Registry of Canada. Am. J. Epidemiol. 1998;148;6:564–574. https://doi.org/10.1093/oxfordjournals.aje.a009682.

28. Cardis E., Vrijheid M., Blettner M., Gilbert E., Hakama M., Hill C., et al. The 15-Country Collaborative Study of Cancer Risk among Radiation Workers in the Nuclear Industry: Estimates of Radiation-Related Cancer Risk. Radiat. Res. 2007;167;4:396–416. https://doi.org/10.1667/RR0553.1.

29. Roman E., Doyle P., Maconochie N., Davies G., Smith P.G., Beral V. Cancer in Children of Nuclear Industry Employees: Report on Children Aged Under 25 Years from Nuclear Industry Family Study. Brit. Med. J. 1999;318;7196:1443–1450. https://doi.org/10.1136/bmj.318.7196.1443.

30. IARC 1994. IARC Study Group on Cancer Risks among Nuclear Industry Workers. Direct Estimates of Cancer Mortality Due to Low Doses of Ionising Radiation: an International Study. IARC Study Group on Cancer Risk among Nuclear Industry Workers. Lancet. 1994;344;8929:1039–1043. https://doi.org/10.1016/S0140-6736(94)91706-X.

31. Breuer F., Strambi E. Evaluation and Rational Recording of Irradiation Doses of Nuclear Workers. Minerva Fisiconucl. 1966;10;2:165–170 (In Italian.).

32. URL: https://www.iaea.org/sites/default/files/vol40_no2_russian_ru.pdf (Date of Access: 30.12.2022).

33. Yadernaya Industriya Rossii = Nuclear Industry of Russia. Collection of Articles. Ed. Petrosyants A.M., Shchegelskiy A.V., Kruglov A.K., et al. Moscow, Energoatomizdat Publ., 2000. 1040 p. (In Russ.).

34. URL: https://www.atomic-energy.ru/RPRAEP (Date of Access: 30.12.2022) (In Russ.).

35. Azizova T.V., Bragin Ye.V., Hamada N., Bannikova M.V. Risk Assessment of Senile Cataract Incidence in a Cohort of Nuclear Workers of Mayak Production Association. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2018;63;4:15–21. https://doi.org/10.12737/article-5b83b0430902e8.35861647 (In Russ.).

36. Takhauov R.M., Isubakova D.S., Bronikovskaya Ye.V., Tsymbal O.S., Khalyuzova M.V., Takhauova L.R., et al. The Bank of Biological Samples by Seversk Biophysical Research Center. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2020;65;2:21–26. https://doi.org/10.12737/1024-6177-2020-65-2-21-26. (In Russ.).

37. Ivanov V.K., Tsyb A.F., Agapov A.M., Kaidalov O.V., Maksioutov M.A. et al. Possible Dose Threshold when Forming a Potential Risk Group among Nuclear Industry Personnel. Radiatsiya i Risk = Radiation and Risk. 2005;Special issue1:4–16 (In Russ.).

38. Gouskova А.К. Relation of Clinical Effects and Spatio-Temporal Dose Distribution of Personal of Atomic Industry. Meditsina Ekstremalnykh Situatsiy = Extreme Medicine. 2011;3:5–11 (In Russ.).

39. Tukov A.R., Shafranskiy I.L., Prokhorova O.N., Ziyatdinov M.N. The Incidence of Cataracts and the Radiation Risk of their Occurrence in Liquidators of the Chernobyl Accident, Workers in the Nuclear Industry. Radiatsiya i Risk = Radiation and Risk. 2019;28;1:37–46. https://doi.org/10.21870/0131-3878-2019-28-1-37-46 (In Russ.).

 

 

 PDF (RUS) Full-text article (in Russian)

 

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.01.2022. Accepted for publication: 25.02.2023.

 

 

 

Medical Radiology and Radiation Safety. 2023. Vol. 68. № 2

DOI:10.33266/1024-6177-2023-68-2-5-10

Lina Alhaddad1,2, Andreyan N. Osipov1,3, Sergey Leonov1,4

Radiation-Induced Premature Senescence of Tumor Cells

1School of Biological and Medical Physics, Moscow Institute of Physics and Technology, Dolgoprudny, Russia

2Department of Environmental Sciences, Faculty of Science, Damascus University, Damascus, Syria

3A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia

4 Institute of Cell Biophysics, Pushchino, Russia

Contact person: Andreyan N. Osipov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

CONTENTS

Introduction

Factors and mechanisms of Stress-Associated Secretory Phenotype (SASP)

Morphological and transcriptional signatures of SASP

Radiation-induced signaling pathways associated with premature senescence

Conclusion

Keywords: ionizing radiation, premature senescence, stress, tumor cells

 

For citation: Alhaddad L, Osipov AN, Leonov S. Radiation-Induced Premature Senescence of Tumor Cells. Medical Radiology and Radiation Safety. 2023;68(2):5–10. (In Russian). DOI: 10.33266/1024-6177-2023-68-2-5-10

 

References

1. Roninson I.B. Tumor Cell Senescence in Cancer Treatment. Cancer Research. 2003;63;11:2705-2715. 

2. Olovnikov A.M. [Principle of Marginotomy in Template Synthesis of Polynucleotides]. Doklady Akademii Nauk SSSR. 1971;201;6:1496-1499. 

3. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic Ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a. Cell. 1997;88;5:593-602. doi: 10.1016/s0092-8674(00)81902-9.

4. Fridlyanskaya I., Alekseenko L., Nikolsky N. Senescence as a General Cellular Response to Stress: A Mini-Review. Experimental Gerontology. 2015;72:124-128. doi: 10.1016/j.exger.2015.09.021.

5. Suzuki M., Boothman D.A. Stress-Induced Premature Senescence (SIPS)--Influence of SIPS on Radiotherapy. Journal of Radiation Research. 2008;49;2:105-112. doi: 10.1269/jrr.07081.

6. Aliper A.M., Bozdaganyan M.E., Orekhov P.S., Zhavoronkov A., Osipov A.N. Replicative and Radiation-Induced Aging: a Comparison of Gene Expression Profiles. Aging (Albany NY). 2019;11;8:2378-2387. doi: 10.18632/aging.101921.

7. Crompton N.E. Telomeres, Senescence and Cellular Radiation Response. Cellular and Molecular Life Sciences: CMLS. 1997;53;7:568-575. doi: 10.1007/s000180050073.

8. Sabbatinelli J., Prattichizzo F., Olivieri F., Procopio A.D., Rippo M.R., Giuliani A. Where Metabolism Meets Senescence: Focus on Endothelial Cells. Frontiers in Physiology. 2019;10:1523. doi: 10.3389/fphys.2019.01523.

9. Coppe J.P., Patil C.K., Rodier F., Sun Y., Munoz D.P., Goldstein J., et al. Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor. PLoS Biology. 2008;6;12:2853-2868. doi: 10.1371/journal.pbio.0060301.

10. Byun H.O., Lee Y.K., Kim J.M., Yoon G. From Cell Senescence to Age-Related Diseases: Differential Mechanisms of Action of Senescence-Associated Secretory Phenotypes. BMB Reports. 2015;48;10:549-558. doi: 10.5483/bmbrep.2015.48.10.122.

11. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., et al. Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network. Cell. 2008;133;6:1019-31. doi: 10.1016/j.cell.2008.03.039.

12. Acosta J.C., O’Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., et al. Chemokine Signaling Via the CXCR2 Receptor Reinforces Senescence. Cell. 2008;133;6:1006-1018. doi: 10.1016/j.cell.2008.03.038.

13. Hornebeck W., Maquart F.X. Proteolyzed Matrix as a Template for the Regulation of Tumor Progression. Biomedicine & Pharmacotherapy. 2003;57;5-6:223-230. doi: 10.1016/s0753-3322(03)00049-0.

14. Brew K., Dinakarpandian D., Nagase H. Tissue Inhibitors of Metalloproteinases: Evolution, Structure and Function. Biochimica et Biophysica Acta. 2000;1477;1-2:267-283. doi: 10.1016/s0167-4838(99)00279-4.

15. Coppe J.P., Desprez P.Y., Krtolica A., Campisi J. The Senescence-Associated Secretory Phenotype: the Dark Side of Tumor Suppression. Annual Review of Pathology. 2010;5:99-118. doi: 10.1146/annurev-pathol-121808-102144.

16. d’Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., et al. A DNA Damage Checkpoint Response in Telomere-Initiated Senescence. Nature. 2003;426;6963:194-198. doi: 10.1038/nature02118.

17. Mikula-Pietrasik J., Niklas A., Uruski P., Tykarski A., Ksiazek K. Mechanisms and Significance of Therapy-Induced and Spontaneous Senescence of Cancer Cells. Cellular and Molecular Life Sciences: CMLS. 2020;77;2:213-229. doi: 10.1007/s00018-019-03261-8.

18. Coppe J.P., Kauser K., Campisi J., Beausejour C.M. Secretion of Vascular Endothelial Growth Factor by Primary Human Fibroblasts at Senescence. The Journal of Biological Chemistry. 2006;281;40:29568-2956874. doi: 10.1074/jbc.M603307200.

19. Taddei M.L., Cavallini L., Comito G., Giannoni E., Folini M., Marini A., et al. Senescent Stroma Promotes Prostate Cancer Progression: the Role of miR-210. Molecular Oncology. 2014;8;8:1729-1746. doi: 10.1016/j.molonc.2014.07.009.

20. Kuo P.L., Shen K.H., Hung S.H., Hsu Y.L. CXCL1/GROalpha Increases Cell Migration and Invasion of Prostate Cancer by Decreasing Fibulin-1 Expression Through NF-kappaB/HDAC1 Epigenetic Regulation. Carcinogenesis. 2012;33;12:2477-87. doi: 10.1093/carcin/bgs299.

21 Rodier F., Coppe J.P., Patil C.K., Hoeijmakers W.A., Munoz D.P., Raza S.R., et al. Persistent DNA damage Signalling Triggers Senescence-Associated Inflammatory Cytokine Secretion. Nature Cell Biology. 2009;11;8:973-979. doi: 10.1038/ncb1909.

22. Pazolli E., Alspach E., Milczarek A., Prior J., Piwnica-Worms D., Stewart S.A. Chromatin Remodeling Underlies the Senescence-Associated Secretory Phenotype of Tumor Stromal Fibroblasts that Supports Cancer Progression. Cancer Research. 2012;72;9:2251-2261. doi: 10.1158/0008-5472.CAN-11-3386.

23. Castillo V., Valenzuela R., Huidobro C., Contreras H.R., Castellon E.A. Functional Characteristics of Cancer Stem Cells and Their Role in Drug Resistance of Prostate Cancer. International Journal of Oncology. 2014;45;3:985-994. doi:
10.3892/ijo.2014.2529.

24. Laberge R.M., Sun Y., Orjalo A.V., Patil C.K., Freund A., Zhou L., et al. MTOR Regulates the Pro-Tumorigenic Senescence-Associated Secretory Phenotype by Promoting IL1A Translation. Nature Cell Biology. 2015;17;8:1049-1061. doi: 10.1038/ncb3195.

25. Herranz N., Gallage S., Mellone M., Wuestefeld T., Klotz S., Hanley C.J., et al. mTOR Regulates MAPKAPK2 Translation to Control the Senescence-Associated Secretory Phenotype. Nature Cell Biology. 2015;17;9:1205-1217. doi: 10.1038/ncb3225.

26. Narita M., Young A.R., Arakawa S., Samarajiwa S.A., Nakashima T., Yoshida S., et al. Spatial Coupling of mTOR and Autophagy Augments Secretory Phenotypes. Science. 2011;332;6032:966-970. doi: 10.1126/science.1205407.

27. Chien Y., Scuoppo C., Wang X., Fang X., Balgley B., Bolden J.E., et al. Control of the Senescence-Associated Secretory Phenotype by NF-kappaB Promotes Senescence and Enhances Chemosensitivity. Genes & Development. 2011;25;20:2125-2136. doi: 10.1101/gad.17276711.

28. Wiley C.D., Velarde M.C., Lecot P., Liu S., Sarnoski E.A., Freund A., et al. Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. Cell Metabolism. 2016;23;2:303-314. doi: 10.1016/j.cmet.2015.11.011.

29. Ksiazek K., Korybalska K., Jorres A., Witowski J. Accelerated Senescence of Human Peritoneal Mesothelial Cells Exposed to High Glucose: the Role of TGF-beta1. Laboratory Investigation; a Journal of Technical Methods and Pathology. 2007;87;4:345-356. doi: 10.1038/labinvest.3700519.

30. Chondrogianni N., Stratford F.L., Trougakos I.P., Friguet B., Rivett A.J., Gonos E.S. Central Role of the Proteasome in Senescence and Survival of Human Fibroblasts: Induction of a Senescence-Like Phenotype Upon Its Inhibition and Resistance to Stress Upon Its Activation. The Journal of Biological Chemistry. 2003;278;30:28026-28037. doi: 10.1074/jbc.M301048200.

31. Keyes W.M., Wu Y., Vogel H., Guo X., Lowe S.W., Mills A.A. p63 Deficiency Activates a Program of Cellular Senescence and Leads to Accelerated Aging. Genes & Development. 2005;19;17:1986-1999. doi: 10.1101/gad.342305.

32. Stein G.H., Drullinger L.F., Soulard A., Dulic V. Differential Roles for Cyclin-Dependent Kinase Inhibitors p21 and p16 in the Mechanisms of Senescence and Differentiation in Human Fibroblasts. Mol. Cell. Biol. 1999;19;3:2109-2117. doi: 10.1128/MCB.19.3.2109.

33. Macip S., Igarashi M., Fang L., Chen A., Pan Z.Q., Lee S.W., et al. Inhibition of p21-Mediated ROS Accumulation Can Rescue p21-Induced Senescence. EMBO J. 2002;21;9:2180-2188. doi: 10.1093/emboj/21.9.2180.

34. Bae G.U., Seo D.W., Kwon H.K., Lee H.Y., Hong S., Lee Z.W., et al. Hydrogen Peroxide Activates p70(S6k) Signaling Pathway. The Journal of Biological Chemistry. 1999;274;46:32596-32602. doi: 10.1074/jbc.274.46.32596.

35. Radisavljevic Z.M., Gonzalez-Flecha B. TOR Kinase and Ran Are Downstream from PI3K/Akt in H2O2-Induced Mitosis. Journal of Cellular Biochemistry. 2004;91;6:1293-1300. doi: 10.1002/jcb.20037.

36. Krouwer V.J., Hekking L.H., Langelaar-Makkinje M., Regan-Klapisz E., Post J.A. Endothelial Cell Senescence is Associated with Disrupted Cell-Cell Junctions and Increased Monolayer Permeability. Vascular Cell. 2012;4;1:12. doi: 10.1186/2045-824X-4-12.

37. Ksiazek K., Piatek K., Witowski J. Impaired Response to Oxidative Stress in Senescent Cells May Lead to Accumulation of DNA Damage in Mesothelial Cells from Aged Donors. Biochemical and Biophysical Research Communications. 2008;373;2:335-339. doi: 10.1016/j.bbrc.2008.06.026.

38. Sidler C., Kovalchuk O., Kovalchuk I. Epigenetic Regulation of Cellular Senescence and Aging. Frontiers in Genetics. 2017;8:138. doi: 10.3389/fgene.2017.00138.

39. Calio A., Zamo A., Ponzoni M., Zanolin M.E., Ferreri A.J., Pedron S., et al. Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21;22:5164-5172. doi: 10.1158/1078-0432.CCR-15-0508.

40. Gorgoulis V., Adams P.D., Alimonti A., Bennett D.C., Bischof O., Bishop C., et al. Cellular Senescence: Defining a Path Forward. Cell. 2019;179;4:813-827. doi: 10.1016/j.cell.2019.10.005.

41. Evangelou K., Lougiakis N., Rizou S.V., Kotsinas A., Kletsas D., Munoz-Espin D., et al. Robust, Universal Biomarker Assay to Detect Senescent Cells in Biological Specimens. Aging Cell. 2017;16;1:192-197. doi: 10.1111/acel.12545.

42. Hansel C., Jendrossek V., Klein D. Cellular Senescence in the Lung: The Central Role of Senescent Epithelial Cells. International Journal of Molecular Sciences. 2020;21;9. doi: 10.3390/ijms21093279.

43. Gire V., Roux P., Wynford-Thomas D., Brondello J.M., Dulic V. DNA Damage Checkpoint Kinase Chk2 Triggers Replicative Senescence. The EMBO Journal. 2004;23;13:2554-2563. doi: 10.1038/sj.emboj.7600259.

44. Naka K., Tachibana A., Ikeda K., Motoyama N. Stress-Induced Premature Senescence in hTERT-Expressing Ataxia Telangiectasia Fibroblasts. The Journal of Biological Chemistry. 2004;279;3:2030-2037. doi: 10.1074/jbc.M309457200.

45. Sikora E., Czarnecka-Herok J., Bojko A., Sunderland P. Therapy-Induced Polyploidization and Senescence: Coincidence or Interconnection? Seminars in Cancer Biology. 2022;81:83-95. doi: 10.1016/j.semcancer.2020.11.015.

46. Wang Q., Wu P.C., Dong D.Z., Ivanova I., Chu E., Zeliadt S., et al. Polyploidy Road to Therapy-Induced Cellular Senescence and Escape. International Journal of Cancer. 2013;132;7:1505-1515. doi: 10.1002/ijc.27810.

47. Leong W.F., Chau J.F., Li B. p53 Deficiency Leads to Compensatory Up-Regulation of p16INK4a. Molecular Cancer Research: MCR. 2009;7;3:354-360. doi: 10.1158/1541-7786.MCR-08-0373.

48. Han Z., Wei W., Dunaway S., Darnowski J.W., Calabresi P., Sedivy J., et al. Role of p21 in Apoptosis and Senescence of Human Colon Cancer Cells Treated with Camptothecin. The Journal of Biological Chemistry. 2002;277;19:17154-17160. doi: 10.1074/jbc.M112401200.

49. Alani R.M., Young A.Z., Shifflett C.B. Id1 Regulation of Cellular Senescence Through Transcriptional Repression of p16/Ink4a. Proceedings of the National Academy of Sciences of the United States of America. 2001;98;14:7812-7816. doi: 10.1073/pnas.141235398.

50. Liu D., Hornsby P.J. Senescent Human Fibroblasts Increase the Early Growth of Xenograft Tumors Via Matrix Metalloproteinase Secretion. Cancer Research. 2007;67;7:3117-3126. doi: 10.1158/0008-5472.CAN-06-3452.

51. Mikula-Pietrasik J., Sosinska P., Maksin K., Kucinska M.G., Piotrowska H., Murias M., et al. Colorectal Cancer-Promoting Activity of the Senescent Peritoneal Mesothelium. Oncotarget. 2015;6;30:29178-29195. doi: 10.18632/oncotarget.4932.

52. Wang T., Notta F., Navab R., Joseph J., Ibrahimov E., Xu J., et al. Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes. Molecular Cancer Research: MCR. 2017;15;1:3-14. doi: 10.1158/1541-7786.MCR-16-0192.

53. Mikula-Pietrasik J., Sosinska P., Naumowicz E., Maksin K., Piotrowska H., Wozniak A., et al. Senescent Peritoneal Mesothelium Induces a Pro-Angiogenic Phenotype in Ovarian Cancer Cells in Vitro and in a Mouse Xenograft Model in Vivo. Clinical & Experimental Metastasis. 2016;33;1:15-27. doi: 10.1007/s10585-015-9753-y.

54. Ruhland M.K., Loza A.J., Capietto A.H., Luo X., Knolhoff B.L., Flanagan K.C., et al. Stromal Senescence Establishes an Immunosuppressive Microenvironment that Drives Tumorigenesis. Nature Communications. 2016;7:11762. doi: 10.1038/ncomms11762.

55. Rovillain E., Mansfield L., Caetano C., Alvarez-Fernandez M., Caballero O.L., Medema R.H., et al. Activation of Nuclear Factor-Kappa B Signalling Promotes Cellular Senescence. Oncogene. 2011;30;20:2356-2366. doi: 10.1038/onc.2010.611.

56. Mirzayans R., Andrais B., Kumar P., Murray D. Significance of Wild-Type p53 Signaling in Suppressing Apoptosis in Response to Chemical Genotoxic Agents: Impact on Chemotherapy Outcome. International Journal of Molecular Sciences. 2017;18;5. doi: 10.3390/ijms18050928.

57. Schmitt C.A. Cellular Senescence and Cancer Treatment. Biochimica et Biophysica Acta. 2007;1775;1:5-20. doi: 10.1016/j.bbcan.2006.08.005.

58. Бородкина А., Дерябин П., Грюкова А., Никольский Н. “Социальная жизнь” стареющих клеток: что такое SASP и зачем его изучать? // Acta Naturae. 2018. Т.10, № 1. С. 4-15. [Borodkina A., Deryabin P., Gryukova A., Nikolskiy N.»Social Life» of Senescent Cells: what Is SASP and why Study It? Acta Naturae. 2018;10;1:4-15 (In Russ.)].

59. Yahyapour R., Salajegheh A., Safari A., Amini P., Rezaeyan A.., Amraee A, et al. Radiation-Induced Non-Targeted Effect and Carcinogenesis; Implications in Clinical Radiotherapy. Journal of Biomedical Physics & Engineering. 2018;8;4:435-446. 

60. Luo H., Yount C., Lang H., Yang A., Riemer E.C., Lyons K., et al. Activation of p53 with Nutlin-3a Radiosensitizes Lung Cancer Cells Via Enhancing Radiation-Induced Premature Senescence. Lung Cancer. 2013;81;2:167-173. doi: 10.1016/j.lungcan.2013.04.017.

61. He X., Yang A., McDonald D.G., Riemer E.C., Vanek K.N., Schulte B.A., et al. MiR-34a Modulates Ionizing Radiation-Induced Senescence In Lung Cancer Cells. Oncotarget. 2017;8;41:69797-69807. doi: 10.18632/oncotarget.19267.

62. Mirzayans R., Scott A., Cameron M., Murray D. Induction of Accelerated Senescence by Gamma Radiation In Human Solid Tumor-Derived Cell Lines Expressing Wild-Type TP53. Radiation Research. 2005;163;1:53-62. doi: 10.1667/rr3280.

63. Mirzayans R., Andrais B., Scott A., Wang Y.W., Kumar P., Murray D. Multinucleated Giant Cancer Cells Produced in Response to Ionizing Radiation Retain Viability and Replicate Their Genome. International Journal of Molecular Sciences. 2017;18;2. doi: 10.3390/ijms18020360.

64. Liao E.C., Hsu Y.T., Chuah Q.Y., Lee Y.J., Hu J.Y., Huang T.C., et al. Radiation Induces Senescence and a Bystander Effect Through Metabolic Alterations. Cell Death & Disease. 2014;5:e1255. doi: 10.1038/cddis.2014.220.

65. Xu J., Patel N.H., Saleh T., Cudjoe E.K., Jr., Alotaibi M., Wu Y., et al. Differential Radiation Sensitivity in p53 Wild-Type and p53-Deficient Tumor Cells Associated with Senescence but not Apoptosis or (Nonprotective) Autophagy. Radiation Research. 2018;190;5:538-557. doi: 10.1667/RR15099.1.

66. Jallepalli P.V., Waizenegger I.C., Bunz F., Langer S., Speicher M.R., Peters J.M., et al. Securin is Required for Chromosomal Stability in Human Cells. Cell. 2001;105;4:445-457. doi: 10.1016/s0092-8674(01)00340-3.

67. Tfelt-Hansen J., Kanuparthi D., Chattopadhyay N. The Emerging Role of Pituitary Tumor Transforming Gene in Tumorigenesis. Clinical Medicine & Research. 2006;4;2:130-137. doi: 10.3121/cmr.4.2.130.

68. Jeon H.Y., Kim J.K., Ham S.W., Oh S.Y., Kim J., Park J.B., et al. Irradiation Induces Glioblastoma Cell Senescence and Senescence-Associated Secretory Phenotype. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Me-
dicine. 2016;37;5:5857-5867. doi: 10.1007/s13277-015-4439-2.

69. Lee J.J., Kim B.C., Park M.J., Lee Y.S., Kim Y.N., Lee B.L., et al. PTEN Status Switches Cell Fate between Premature Senescence and Apoptosis in Glioma Exposed to Ionizing Radiation. Cell Death and Differentiation. 2011;18;4:666-677. doi: 10.1038/cdd.2010.139.

 

 PDF (RUS) Full-text article (in Russian)

 
Conflict of interest. The authors declare no conflict of interest.

Financing. The work was carried out with the financial support of RFBR grant No. 20-34-90035.

Contribution. L. Alkhaddad – collection and analysis of literary material, writing the text. A.N. Osipov and S.V. Leonov – concept development and scientific editing.

Article received: 20.11.2022. Accepted for publication: 25.01.2023.

 

 

Medical Radiology and Radiation Safety. 2023. Vol. 68. № 3

   

РЕЦЕНЗИЯ

НА РЕКОМЕНДАЦИИ РОСГИДРОМЕТА Р 52.18.787-2013 «МЕТОДИКА ОЦЕНКИ РАДИАЦИОННЫХ РИСКОВ НА ОСНОВЕ ДАННЫХ МОНИТОРИНГА РАДИАЦИОННОЙ ОБСТАНОВКИ» И Р 52.18.923-2022 «ПОРЯДОК ОЦЕНКИ РИСКА
ОТ РАДИОАКТИВНОГО ЗАГРЯЗНЕНИЯ ОКРУЖАЮЩЕЙ СРЕДЫ ПО ДАННЫМ МОНИТОРИНГА РАДИАЦИОННОЙ ОБСТАНОВКИ».

  

Согласно Федеральному закону от 21.11.2011 №331-ФЗ (ред. от 21.12.2021) «О внесении изменений в Федеральный закон «Об охране окружающей среды» и отдельные законодательные акты Российской Федерации» (статья 7, п. 6) государственный мониторинг радиационной обстановки на территории РФ осуществляется в целях своевременного выявления изменений радиационной обстановки, оценки, прогнозирования и предупреждения возможных негативных последствий радиационного воздействия для населения и окружающей среды. Комплексным показателем состояния радиационной обстановки является риск от радиоактивного загрязнения окружающей среды. Специалистами ФГБУ «НПО «Тайфун» разработаны рекомендации с методиками оценки радиационного риска для человека (Р 52.18.787-2013) и окружающей среды (Р 52.18.923-2022) на основе данных мониторинга радиационной обстановки.

Методика оценки риска для человека позволяет оценить уровни радиационного риска на основе обобщенных данных мониторинга радиационной обстановки в компонентах природной среды. В ней изложены основные принципы и критерии методологии оценки радиационных рисков, порядок проведения анализа данных мониторинга радиационной обстановки, даны детальные рекомендации по статистическому анализу данных с учетом пространственной неоднородности и временных изменений распределения радионуклидов в компонентах природной среды (определение выборочного среднего арифметического значения, стандартного отклонения анализируемой выборки, анализ на нормальность с расчетами статистических толерантных интервалов), по анализу неопределенностей результатов оценки радиационного риска. В случае отсутствия или недостаточности данных мониторинга радиационной обстановки выполняются расчетные оценки при помощи моделей, позволяющих использовать специфические (региональные) параметры.

Оценки радиационного риска могут производиться как по отдельным путям радиационного воздействия, так и суммарного радиационного риска, на основе анализа сценариев множественных путей радиационного воздействия. Сценарий радиационного воздействия составляется исходя из целей оценки радиационного риска, данным мониторинга радиационной обстановки и концептуальной модели радиоактивно загрязненной территории.

В методике приведен пример оценки радиационного риска с использованием данных многолетнего мониторинга радиационной обстановки (РО) в районе расположения Балаковской АЭС. Представленный пример включает:

- описание географического положения Балаковской АЭС,

- характеристику данных мониторинга РО в зоне наблюдения (ЗН) и 100-км зоне вокруг АЭС,

- данные наблюдения и измерений активности в атмосферном воздухе, поверхностных водах и почве в ЗН объекта,

- данные мониторинга радиационной обстановки по удельной активности радионуклидов в продуктах питания, произведенных в ЗН,

- определение обобщенных параметров модели оценки радиационного риска на основе статистического анализа данных мониторинга РО (атмосферный воздух, почва, продукты питания (мясо, молоко, зерновые, рыба)),

- расчет недостающих параметров анализа радиационного риска на основе моделей (расчет удельных активностей радионуклидов в продуктах питания),

- сводные результаты расчетов удельных активностей радионуклидов в продуктах питания и питьевой воде в ЗН и контрольном участке,

- результаты расчета радиационного риска по данным мониторинга РО в ЗН и на контрольном участке,

- применение результатов оценки радиационного риска к оптимизации мониторинга РО и оценкам интегрального радиационного воздействия от радиоактивного загрязнения компонентов природной среды.

Важным достоинством методики оценки радиационного риска является переход от множества данных мониторинга радиационной обстановки к единому интегральному показателю – уровню радиационного риска. Под понятием «радиационный риск» в методике Р 52.18.787-2013 подразумевается вероятность возникновения у человека или его потомства какого-либо вредного эффекта в результате облучения.

Данная методика апробирована для ряда радиационно опасных объектов и широко используется специалистами.

Рекомендации Р 52.18.923-2022 содержат основные положения, принципы и методы оценки экологического риска от радиоактивного загрязнения окружающей среды на основе показателей радиационного фона и контрольных уровней содержания радионуклидов в компонентах природной среды, с учетом требований национальных нормативных документов РФ.

Рекомендации включают порядок оценки показателей, используемых для оценки риска от радиоактивного загрязнения окружающей среды: индекса экологического риска (ИЭР – отношение мощности дозы облучения референтных организмов к предельно допустимой радиационной нагрузке (ПДРН)), интегрального показателя загрязнения радионуклидами компонентов природной среды (ИПЗ – сумма отношений наблюдаемых концентраций радионуклидов в компонентах природной среды к соответствующим рассчитанным контрольным уровням), обобщенного показателя риска от радиоактивного загрязнения окружающей среды (ОПР – интегральный показатель оценки радиационной обстановки с учетом пространственного масштаба, продолжительности и интенсивности радиационного воздействия на компоненты природной среды).

Расчет рисков производится на основе радиационного и экологического критериев, обеспечивающих сохранение благоприятной окружающей среды. В связи с большим биоразнообразием экосистем оценки риска производятся для ограниченного набора референтных организмов: почвенные беспозвоночные, наземные млекопитающие, травянистая растительность, деревья, птицы, земноводные, пресмыкающиеся, макроводоросли, рыба (пелагическая и придонная), бентос, водные млекопитающие.

Рекомендации предлагают порядок оценки риска от радиоактивного загрязнения окружающей среды по данным мониторинга радиационной обстановки (федеральной сети радиометрических наблюдений, территориальной и локальной систем наблюдений) на основе показателей радиационного фона и контрольных уровней содержания радионуклидов в компонентах природной среды. Расчет рисков производится на основе радиационного и экологического критериев, обеспечивающих сохранение благоприятной окружающей среды.

Для оценки радиационной обстановки в Рекомендациях определено шкалирование экологических радиационных рисков с учетом пространственного масштаба, продолжительности и интенсивности радиационного воздействия на компоненты природной среды:

–          недопустимый риск (НДР), при котором дозы облучения референтных организмов достигают или превышают ПДРН (ИЭР≥1), либо ИПЗ≥1;

–          экологически приемлемый риск (ЭПР), при котором дозы облучения референтных организмов не менее чем в 10 раз ниже ПДРН (ИЭР<0,1), либо ИПЗ<0,1;

–          незначительное радиационное воздействие, при котором дозы облучения референтных организмов не отличаются значимо от радиационного фона.

Использование методики оценки радиационного риска дает современный метод интегральной оценки радиационного состояния окружающей среды.

Данные рекомендациимогут быть применены для:

−        анализа и интерпретации информации о радиационных рисках на территории РФ по данным мониторинга радиационной обстановки с учетом требований в области охраны окружающей среды (природоохранных требований);

−        оценки состояния и изменений радиационной обстановки под воздействием природных и антропогенных факторов, в т.ч. в районах расположения радиационных объектов;

−        совершенствования мониторинга радиационной обстановки;

−        получения достоверной информации об интегральном уровне радиационного воздействия на окружающую среду и ее интерпретации на основе концепции экологического риска с целью обеспечения сохранения благоприятной окружающей среды.

В отличие от методики 2013 г., в методике 2022 г. под «экологическим радиационным риском» (риском от радиоактивного загрязнения окружающей среды) понимается мера радиационного воздействия на природные объекты, способного привести к неблагоприятным экологическим последствиям. В основе данной методики лежит постулат порогового действия ионизирующего излучения на организмы.

Выполнена апробация Рекомендаций по оценке риска в зонах наблюдения объектов использования атомной энергии (Белоярская АЭС, Ленинградская АЭС, Нововоронежская АЭС, ПАО «ППГХО») по данным мониторинга радиационной обстановки в 2000-2021 гг. Результаты апробации опубликованы в ряде научных публикаций, а также в Российском национальном докладе «35 лет Чернобыльской аварии. Итоги и перспективы преодоления ее последствий в России (1986-2021)». Апробация Рекомендаций по данным многолетнего мониторинга свидетельствует об их работоспособности и возможности практического применения для оценки радиоэкологической обстановки в районах расположения объектов использования атомной энергии.

Результаты оценки радиационного риска при помощи рекомендаций Р 52.18.787-2013 и Р 52.18.923-2022 позволяют выполнить идентификацию и ранжирование факторов радиационного воздействия, рационально организовать мониторинг радиационной обстановки, обеспечить возможность достоверной оценки экологических последствий радиационных аварий и выбрать наиболее эффективные меры по преодолению их негативного влияния на окружающую среду, оптимизировать защитные меры с целью сохранения благоприятной окружающей среды и обеспечению приемлемого уровня радиационного экологического риска. Результаты оценки риска от радиоактивного загрязнения окружающей среды важны при разработке и принятии решения о необходимости проведения природоохранных мероприятий.

 

 

Г.В. Лаврентьева, доктор биологических наук, доцент,
Заведующая кафедрой «Биотехнические системы и технологии»
Калужского филиала Московского государственного технического университета
им. Н.Э. Баумана (национального исследовательского университета)
(КФ МГТУ им. Н.Э. Баумана)

 

Б.И. Сынзыныс, доктор биологических наук,
профессор, профессор Отделения ядерной физики и технологий
Обнинского института атомной энергетики – филиала
Национального исследовательского ядерного
университета «МИФИ» (ИАТЭ НИЯУ МИФИ)

 

 

 PDF (RUS) Full-text article (in Russian)

 

 

 

 

 

Medical Radiology and Radiation Safety. 2023. Vol. 68. № 2

DOI: 10.33266/1024-6177-2023-68-2-16-20

Yu.B. Deshevoi, T.A. Nasonova, O.A. Dobrynina, V.G. Lebedev,
T.A. Astrelina, A.S. Samoylov

The Effect of Drugs for Normalize Blood Supply and Trophism of Irradiated Tissues,  as well as a Broad-Spectrum Antibiotic on the Course of Severe Local Radiation Injuries in Rats

A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia

Contact person: Yu.B. Deshevoi, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

ABSTRACT

Purpose: To study in the experiment the therapeutic efficacy of drugs that normalize blood supply and trophism of irradiated tissues, as well as a complex broad-spectrum antibiotic, for the course of severe local radiation lesions to justify the clinical use of these drugs in this pathology. 

Material and methods: Wistar-Kyoto inbred rats were exposed to local X-rays in the ilio-lumbar region of the back at a dose of 110 Gy (tube voltage 30 kV, current 6.1 mA, Al filter 0.1 mm thick), at a dose rate of 20.1 Gy / min. Irradiation field area was 8.5 cm2. Radiation exposure caused the formation of long-term (up to 3.5–4 months) non-healing radiation ulcers of the skin without a critical radiation load on the underlying tissues. For the treatment of radiation lesions, an antibiotic was used – levotetrasulfin forte, as well as drugs that affect the blood supply and trophism of irradiated tissues – pentoxifylline and detralex. The drugs were administered daily both in isolation from each other and together during the period (from the 21st to the 42nd or from the 28th to the 48th day after irradiation), when the radiation ulcer formed and its gradual healing began. The everity of radiation skin lesions and the effects of therapy were assessed in dynamics by clinical manifestations and using planimetry.

Results: It was found that the separate use of drugs in the treatment of severe local radiation lesions was not very effective. However, with the combined administration of drugs, a noticeable increase in the rate of healing of radiation ulcers was revealed. Thus, it was shown that with the joint administration of pentoxifylline (intraperitoneal, 50.0 mg / kg), detralex (75.0 mg / kg, per os) and levotetrasulfin forte (intraperitoneal, 0.1 ml / kg), the area of radiation ulcers in treated animals in the period from 98 to 126 days after irradiation was 26–80 % less compared to irradiated controls. 

Conclusion: The experiments show the possibility of successful use of a complex antibiotic in combination with drugs that improve blood supply and trophism of irradiated tissues, in the treatment of severe local radiation lesions.

Keywords: local irradiation, radiation ulcer of the skin, drug therapy, antibiotic, pentoxifylline, detralex, rats

For citation: Deshevoi YuB, Nasonova TA, Dobrynina OA, Lebedev VG, Astrelina TA, Samoylov AS. The Effect of Drugs for Normalize Blood Supply and Trophism of Irradiated Tissues, as well as a Broad-Spectrum Antibiotic on the Course of Severe Local Radiation Injuries in Rats. Medical Radiology and Radiation Safety. 2023;68(2):16–20. (In Russian). DOI: 10.33266/1024-6177-2023-68-2-16-20

 

References

1.Radiatsionnaya Meditsina = Radiation Medicine. A Guide for Medical Researchers and Health Care Organizers. Ed. Ilin L.A. Moscow, Izdat Publ., 2001. V.2. 432 p. (In Russ.).

2.Nadezhina N.M., Galstyan I.A. Lecheniye Mestnykh Luchevykh Porazheniy = Treatment of Local Radiation Lesions. Ed. Kotenko R.V., Bushmanov A.,Yu. Moscow, A.I. Burnasyan FMBC Publ., 2013. 99 p. (In Russ.).

3.Afrikanova L.A. Ostraya Luchevaya Travma Kozhi = Acute Radiation Trauma of the Skin. Moscow, Meditsina Publ.,1975. 192 p. (In Russ.).

4.Vorobyev Ye.I., Stepanov R.P. Ioniziruyushcheye Izlucheniye i Krovenosnyye Sosudy = Ionizing Radiation and Blood Vessels. Moscow, Energoatomizdat Publ., 1985. 296 p. (In Russ.).

5.Satyamitra M.M., DiCarlo A.L. Understanding the Pathophysiology and Challenges of Development o of Medical Countermeasures for Radiation-Induced Vascular/Endothelial Cell Injuries: Report of NIAID Workshop, August 20, 2015. Radiation Research. 2016;186;2:99-111.

6.Kolev M., Donchev N., Borov M. Experimental Research on the Toxicity of Pharmapentoxifylline. Exp. Med. Morhpol. 1990;29;4:57-61.

7.Product Monograph. PrTRENTAL®. ATC Code: C04AD03. Sanofi-Aventis Canada Inc, 2011. 21 p.

8.Bogachev V.Yu., Boldin B.V., Turkin P.Yu. Comparative Effectiveness of Various Methods of Treatment of Chronic Venous Edema in Real Clinical Practice. Angiologiya i Sosudistaya Khirurgiya = Angiology and Vascular Surgery. 2021;21;3:77-83 (In Russ.).

9.Man M.Q., Yang B., Elias P.M. Benefits of Hesperidin for Cutaneous Functions. Hindawi Evidence-Based Complementary and Alternative Medicine. 2019;2019;2676307:19. URL: https://doi.org/10.1155/2019/2676307.

10.Gunik A.V., Parshin P.A., Vostroilova G.A. Parameters of Toxicity of the Complex Antimicrobial Drug Levoterasulfine Forte. Aktualnyye Problemy Bolezney Molodnyaka v Sovremennykh Usloviyakh = Actual Problems of Diseases of Young Animals in Modern Conditions. The Materials of the International Scientific and Practical Conference. Voronezh, September 23-25, 2002. Voronezh Publ., 2002. P. 11 (In Russ.).

11.Nieder C., Zimmermann F.B., Adam M., Molls M. The Role of Pentoxifylline as a Modifier of Radiation Therapy. Cancer Treatment Reviews. 2005;31:448-455.

12.Delanian S., Lefaix J. Current Management for Late Normal Tissue Injury: Radiation-Induced Fibrosis and Necrosis. Semin. Radiat. Oncol. 2007;17:99-107.

13.Boerma M., Roberto K.A., Hauer-Jensen M. Prevention and Treatment of Functional and Structural Radiation Injury in the Rat Heart by Pentoxifylline and Alpha-Tocopherol. Int. J. Radiol. Oncol. Biol. Phys. 2008;72;1:170-177.

14.Sezer A., Ustra U., Kosak Z., Yagci M.A. The Effect of Flavonoid Fractions Diosmin + Hesperidin on Radiation-Induced Acute Proctitis in Rat Model. J. Can. Res. Ther. 2011;7;2:152-156.

15.Jagetia G.C., Rao K.V.N.M. Topical Application of Hesperidin, a Citrus Bioflavonone Accelerates Healing of Full Thickness Dermal Excision Wounds of Mice Exposed to 6 Gy of Whole Body γ-Radiation. SM J. Nutr. Metab. 2017;3;2:1021. 

16.Dion M.W., Hussey D.H., Osborne J.W. The Effect of Pentoxifylline on Early and Late Radiation Injury Following Fractionated Irradiation in C3H Mice. Int. J. Radiat. Oncol. Biol. Phys. 1989;17;1:101-107.

17.Olascoaga A., Vilar-Compte D., Poitevin-Chacon A., Contreras-Ruis J. Wound Healing in Radiation Skin Pathophysiology and Treatments Options. Int. Wound J. 2008;2008:2:246-257.

18.Kotenko K.V., Moroz B.B., Nasonova T.A., et al. Experimental model of severe local radiation injuries of the skin after x-rays. Patologicheskaya Fiziologiya i Eksperimentalnaya Terapiya = Pathological Physiology and Experimental Therapy. 2013;57;4:121-123 (In Russ.).

19.Li Y., Kandhare A.D., Mukherjee A.A., Bodhankar S.L. Acute and Sub-Chronic Oral Toxicity Studies of Hesperidin Isolated from Orange Peel Extract in Sprague Dawley Rats. Regulary Toxicology and Pharmacology. 2019;105:77-85.

20.Meyer O.C. Safety and Security Daflon 500 mg in Venus Insufficiency and Hemorrhoidal Diseases. Angiology.1994;45;6(Suppl. 2):579-584.

 

 

 PDF (RUS) Full-text article (in Russian)


Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.11.2022. Accepted for publication: 25.01.2023.

 

 

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

2764483
Today
Yesterday
This week
Last week
This month
Last month
For all time
377
4471
22867
18409
72226
75709
2764483


Your IP:216.73.216.155